Source Article

This article summarizes the findings of a scientific study conducted by the Harry Perkins Institute of Medical Research in Western Australia and published in npj Precision Oncology (Nature Portfolio):

Duffy, C., Sorolla, A., et al. (2020).
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.
npj Precision Oncology, 4(24). DOI: 10.1038/s41698-020-00129-0

The biological effects of honeybee venom have gained increasing attention in recent years.
This study by the Harry Perkins Institute highlights how melittin, the major peptide in bee venom, affects aggressive types of breast cancer both in laboratory settings and in live animal models.

Below is a clear and accessible summary of the study’s key findings.

1. Purpose of the Study: What Does Melittin Do to Breast Cancer Cells?

The study examines two difficult-to-treat breast cancer subtypes:

• HER2-positive breast cancer
• Triple-Negative Breast Cancer (TNBC)

Both subtypes progress rapidly and have limited treatment options.
Researchers tested melittin’s biological effects using both in vitro and in vivo methods.

2. How Did Melittin Affect the Cells?

Laboratory findings show that melittin demonstrated significant activity against both cancer types:

• Melittin created microscopic pores in the cancer cell membrane.
• This disrupted structure led to rapid apoptosis (programmed cell death).
• Suppression of HER2 receptor activation halted growth signaling in the cells.
• In TNBC cells, cell migration and invasion capacity was noticeably reduced.

These findings indicate that melittin can exert strong biological effects in a short time.

3. Mouse Models: Results in Living Organisms

A key strength of this study is that it includes data from animal models, not only laboratory environments.

In the study:

• Immunocompromised mice were implanted with HER2+ and TNBC tumor cells,
• Melittin was applied directly to the tumor sites,
• Observations included:
  • Slower tumor growth,
  • In some cases decreases in tumor volume,
  • Suppression of key signaling pathways involved in tumor progression.

This confirms that melittin shows biological activity not only in cell culture but also in living organisms.

4. Overall Conclusion: Melittin Identified as a Potential Candidate

The study concludes:

Melittin, the main component of honeybee venom, demonstrates strong biological activity against HER2-positive and triple-negative breast cancer cells in both laboratory and animal models. These findings suggest that melittin may be considered a potential therapeutic candidate in the future.

This explains why bee venom is drawing increasing scientific interest.

A Note from Beetolia

At Beetolia, we closely follow the natural properties of bee venom and the scientific research being carried out in this field.
We collect high-quality venom with respect for nature and continue to monitor developments regarding the biological characteristics of bee-derived products.